Using genetic testing to personalize warfarin treatment after heart valve replacement surgery in Qatar

Clinical implementation of pharmacogenetic-guided dosing of warfarin in patients with heart valve replacement in Qatar

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN25354156

Enrollment

150

Registered

2026-05-14

Start date

2023-01-22

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients eligible for warfarin after heart valve replacement surgery Circulatory System

Interventions

The prospective cohort genotype-guided strategy (intervention group) of 150 patients will be compared against a traditional retrospective clinical dosing strategy (control group), which will be 300 pa

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 18-75 years old 2. Not used warfarin in the past 3 months 3. Normal international normalised ratio (INR) value of 0.8-1.2 4. Informed consent

Exclusion criteria

Exclusion criteria: 1. History of any other cardiac operation 2. Diagnosis of active cancer/haematological disorders 3. Severe renal/hepatic insufficiency 4. Abnormal thyroid function 5. Pregnancy 6. Inability to provide written consent

Countries

Qatar

Contacts

Public ContactRania Abdel-latif

rabdellatif@qf.org.qa+974 (0)70001383

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 30, 2026